Business
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended June 30, 2024 and Second Quarter of 2024
ZTlido® net sales for the month of June 2024 grew in the range of 70% to 104%, compared to the same period last year.ZTlido® net sales for the quarter ended
About this update from Scilex Holding Company
[{"type":"text","content":"ZTlido® net sales for the month of June 2024 grew in the range of 70% to 104%, compared to the same period last year.ZTlido® net sales for the quarter ended June 2024 grew in the range of 28% to 42%, compared to the same period last year.Total product net sales for the month of June 2024 grew in the range of 77% to 116%, compared to the same period last year.Total product net sales for the quarter ended June 2024 grew in the range of 30% to 44%, compared to the same period last year. PALO ALTO, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today provided certain preliminary unaudited financial results for the month ended June 30, 2024 and quarter ended June 30, 2024. “For the month of June 2024, sales were highlighted by year-over-year growth trends improving in the second half of the second quarter and ZTlido® is surpassing in the month of June with the gross sales in the range of $22.0 million to $26.0 million mark for the first time,” said Jaisim Shah, Chief Executive Officer and President of Scilex. “In addition to ZTlido® expansion across all target market segments, we continue to expect improving sales trends throughout this year for ELYXYB® and our launch of Gloperba® as we broaden education and awareness around these complementary and standalone non-opioid solutions for managing acute pain.” The Company estimates that: ZTlido net sales for the month ended June 30, 2024 were in the range of $7.5 million to $9.0 million, compared to $4.4 million for the same period last year, representing growth in the range of approximately 70% to 104%.ZTlido net sales for the quarter ended June 30, 2024 were in the range of $15.8 million to $17.5 million, compared to $12.3 million for the same period last year, representing growth in the range of approximately 28% to 42%.Total product net sales for the month ended June 30, 2024 were in the range of $7.8 million to $9.5 million, compared to $4.4 million for the same period last year, representing growth in the range of approximately 77% to 116%.Total product net sales for the quarter ended June 30, 2024 were in the range of $16.4 million to $18.2 million, ...